FOXO4-DRIvsHGH 191AA

FOXO4-DRI is a D-retro-inverso (DRI) peptide — a peptide composed entirely of D-amino acids (mirror image of natural L-amino acids) assembled in reverse sequence order. This DRI modification makes the peptide virtually invisible to cellular proteases (which have evolved to cleave L-amino acid peptide bonds), dramatically extending its biological half-life while preserving the spatial orientation of key amino acid side chains needed for target interaction.

The target is the FOXO4-p53 protein-protein interaction that keeps senescent cells alive. Cellular senescence is a state of permanent cell cycle arrest triggered by DNA damage, oncogene activation, or telomere shortening. Senescent cells would normally undergo p53-mediated apoptosis (programmed cell death), but they evade this fate through a survival mechanism: the transcription factor FOXO4 is selectively upregulated in senescent cells and physically binds to p53, sequestering it in PML (promyelocytic leukemia) nuclear bodies. This binding prevents p53 from activating its pro-apoptotic transcriptional program (PUMA, BAX, NOXA), keeping the damaged cell alive.

FOXO4-DRI competitively disrupts this interaction by mimicking the FOXO4 binding interface for p53 but without the nuclear body-localizing function. When FOXO4-DRI competes p53 away from endogenous FOXO4, liberated p53 can access its apoptotic target genes, triggering mitochondrial outer membrane permeabilization and caspase activation — selectively killing the senescent cell. Crucially, non-senescent cells do not depend on FOXO4-p53 interaction for survival (they have intact cell cycle regulation and don't upregulate FOXO4), so they are unaffected by FOXO4-DRI. This selectivity — killing only 'zombie' senescent cells while sparing healthy cells — makes FOXO4-DRI a true senolytic agent. In the original 2017 Cell publication by de Keizer et al., FOXO4-DRI treatment in aged mice reduced senescent cell burden and restored physical fitness, fur density, and renal function.

Human Growth Hormone is a 191-amino-acid single-chain polypeptide secreted by somatotroph cells of the anterior pituitary gland. It exerts its effects through two distinct pathways: direct action via GH receptors and indirect action through insulin-like growth factor 1 (IGF-1). When HGH binds to the GH receptor (a type I cytokine receptor), it induces receptor dimerization and activates the JAK2/STAT5 signaling cascade, which directly stimulates gene transcription for protein synthesis, cell proliferation, and lipolysis.

The indirect pathway is equally important. GH receptor activation in hepatocytes stimulates the production and secretion of IGF-1, a 70-amino-acid peptide that circulates bound to IGF binding proteins (primarily IGFBP-3 and the acid-labile subunit). Circulating IGF-1 acts on virtually every tissue in the body — promoting amino acid uptake and protein synthesis in skeletal muscle, stimulating chondrocyte proliferation in growth plates, enhancing osteoblast activity for bone formation, and supporting neuronal survival and myelination.

GH also has profound effects on metabolism independent of IGF-1. It directly stimulates lipolysis in adipocytes by activating hormone-sensitive lipase, mobilizing stored fat as free fatty acids for energy. It antagonizes insulin action in peripheral tissues (hence the diabetogenic risk), shifting the body's fuel preference from glucose to fatty acids. In muscle, GH promotes nitrogen retention and positive protein balance. The pulsatile pattern of natural GH secretion — with the largest pulse during deep sleep — is important for its physiological effects, which is why exogenous GH protocols often try to mimic this pattern.